Literature DB >> 12103304

HIV/AIDS treatment and HIV vaccines for Africa.

Paul J Weidle1, Timothy D Mastro, Alison D Grant, John Nkengasong, Doris Macharia.   

Abstract

Increased support from the global HIV/AIDS community is driving advances in HIV treatment and vaccine development in the developing world. Care of patients with AIDS includes many biomedical, nutritional, psychosocial, and behavioural interventions. In resource-poor settings, antiretroviral drugs should be given with use of standardised treatment regimens and streamlined algorithms for monitoring use. A safe and effective HIV vaccine will supplement prevention efforts to protect uninfected people against infection, or might possibly be able to modify the course of HIV infection. Advances have been made in understanding the immune response and immunisation to HIV, and new ideas for candidate vaccines have been developed, including several based on HIV-1 strains prevalent in Africa. HIV vaccine efficacy trials are needed in Africa to determine whether these advances can be translated into clinical and public health benefits. In this review, we discuss the prospects for use of treatment and vaccines in resource-poor settings.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12103304     DOI: 10.1016/S0140-6736(02)09297-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

Review 1.  Socio-behaviour challenges to phase III HIV vaccine trials in Sub-Saharan Africa.

Authors:  Joalida Smit; Keren Middelkoop; Landon Myer; Graham Lindegger; Leslie Swartz; Soraya Seedat; Tim Tucker; Robin Wood; Linda-Gail Bekker; Dan J Stein
Journal:  Afr Health Sci       Date:  2005-09       Impact factor: 0.927

2.  Field evaluation of the gag-based heteroduplex mobility assay for genetic subtyping of circulating recombinant forms of human immunodeficiency virus type 1 in Abidjan, Côte d'Ivoire.

Authors:  Souleymane Sawadogo; Christiane Adjé-Touré; Celestin E Bilé; Rene E A Ekpini; Terence Chorba; John N Nkengasong
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

3.  HIV-1 nef suppression by virally encoded microRNA.

Authors:  Shinya Omoto; Masafumi Ito; Yutaka Tsutsumi; Yuko Ichikawa; Harumi Okuyama; Ebiamadon Andi Brisibe; Nitin K Saksena; Yoichi R Fujii
Journal:  Retrovirology       Date:  2004-12-15       Impact factor: 4.602

4.  Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa.

Authors:  Hannah Kibuuka; David Guwatudde; Robert Kimutai; Lucas Maganga; Leonard Maboko; Cecilia Watyema; Fredrick Sawe; Douglas Shaffer; Dickson Matsiko; Monica Millard; Nelson Michael; Fred Wabwire-Mangen; Merlin Robb
Journal:  PLoS One       Date:  2009-04-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.